The current investigation discovered an upregulation of MAP1A in T2DM/HT patients, which could potentially link to the pathogenesis of DM and/or HT, as well as other complications stemming from the activation of DDR proteins and the development of dementia from DDR through p53-mediated RhoB activation. The gene discussed is MAP1A; the disease is hematocrit.